In a combined network meta-analysis, infliximab and adalimumab had the greatest risk for serious infection in patients with plaque psoriasis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback